Dr. Noel Chan is the Principal Investigator on a new PHRI study, LEADER-PAD, investigating if the anti-inflammation therapy, colchicine, is effective in addressing residual vascular risks in people with peripheral artery disease (PAD).
Inflammation in arteries can predispose to the sudden formation of blood clots, which can block the arteries to cause heart attack, stroke and leg gangrene. Surgery to unblock the arteries, blood thinning and blood pressure- and cholesterol-lowering medications can help prevent and treat complications – but still, too many patients with PAD end up with complications.
“Colchicine is an anti-inflammatory medication that reduces complications in patients with angina or heart attack, but it has not been tested in patients with PAD,” Noel Chan notes.
Dr. Chan is an Assistant Professor in the Division of Hematology and Thromboembolism, Department of Medicine, and Investigator at PHRI, specializing in anticoagulant therapy and thrombosis medicine. His research seeks to improve our understanding of the triggers for thrombosis (including the role of inflammation) and the determinants of variable response to antithrombotic therapies to inform on novel strategies that have the potential to further reduce the burden of thrombosis.
Dr. Ashkan Shoamanesh and Dr. Aristeidis Katsanos
Meanwhile, Dr. Ashkan Shoamanesh, Associate Professor and Dr. Aristeidis Katsanos, Assistant Professor, in the Division of of Neurology are co-Principal Investigators on another new study, CoVasc-ICH, looking at whether colchicine can prevent vascular events after an acute intracerebral hemorrhage (ICH).
The two new studies join three ongoing studies at PHRI that are investigating colchicine for other conditions and patient populations.
For more information, visit the PHRI website.